74 related articles for article (PubMed ID: 35551087)
21. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
22. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
23. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.
Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
[TBL] [Abstract][Full Text] [Related]
24. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
26. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
27. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
28. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles.
Orme JJ; Enninga EAL; Lucien-Matteoni F; Dale H; Burgstaler E; Harrington SM; Ball MK; Mansfield AS; Park SS; Block MS; Markovic SN; Yan Y; Dong H; Dronca RS; Winters JL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817395
[TBL] [Abstract][Full Text] [Related]
30. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
Orme JJ; Jazieh KA; Xie T; Harrington S; Liu X; Ball M; Madden B; Charlesworth MC; Azam TU; Lucien F; Wootla B; Li Y; Villasboas JC; Mansfield AS; Dronca RS; Dong H
Oncoimmunology; 2020; 9(1):1744980. PubMed ID: 32363112
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
[TBL] [Abstract][Full Text] [Related]
32. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels.
Sideras K; de Man RA; Harrington SM; Polak WG; Zhou G; Schutz HM; Pedroza-Gonzalez A; Biermann K; Mancham S; Hansen BE; Bart Takkenberg R; van Vuuren AJ; Pan Q; Ijzermans JNM; Sleijfer S; Sprengers D; Dong H; Kwekkeboom J; Bruno MJ
Sci Rep; 2019 Jul; 9(1):10677. PubMed ID: 31337865
[TBL] [Abstract][Full Text] [Related]
33. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.
Padmanabhan A; Connelly-Smith L; Aqui N; Balogun RA; Klingel R; Meyer E; Pham HP; Schneiderman J; Witt V; Wu Y; Zantek ND; Dunbar NM; Schwartz GEJ
J Clin Apher; 2019 Jun; 34(3):171-354. PubMed ID: 31180581
[TBL] [Abstract][Full Text] [Related]
34. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Haslam A; Prasad V
JAMA Netw Open; 2019 May; 2(5):e192535. PubMed ID: 31050774
[TBL] [Abstract][Full Text] [Related]
35. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Poggio M; Hu T; Pai CC; Chu B; Belair CD; Chang A; Montabana E; Lang UE; Fu Q; Fong L; Blelloch R
Cell; 2019 Apr; 177(2):414-427.e13. PubMed ID: 30951669
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
37. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.
Costantini A; Julie C; Dumenil C; Hélias-Rodzewicz Z; Tisserand J; Dumoulin J; Giraud V; Labrune S; Chinet T; Emile JF; Giroux Leprieur E
Oncoimmunology; 2018; 7(8):e1452581. PubMed ID: 30221046
[TBL] [Abstract][Full Text] [Related]
38. Analytical Considerations in Nanoscale Flow Cytometry of Extracellular Vesicles to Achieve Data Linearity.
Gomes J; Lucien F; Cooper TT; Kim Y; Williams KC; Liao X; Kaufman L; Lagugné-Labarthet F; Kenyon O; Boysen J; Kay NE; McIntyre CW; Leong HS
Thromb Haemost; 2018 Sep; 118(9):1612-1624. PubMed ID: 30112749
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
